Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by MineDiggeron Sep 24, 2019 7:18am
107 Views
Post# 30157815

RE:RE:RE:RE:RE:RE:47 MILLION SHARES

RE:RE:RE:RE:RE:RE:47 MILLION SHARES
On the bright side, Bioasis did not fill the July 2018 PP (< $1m of "up to $3m" planned), so here's hoping they only gets a single $m or so, and then maybe we get some better news before the next try.

Not that they are a capital market company, and maybe they have been "discontinued", but I wonder if SternIR is (was) earning their keep? ("2018-10-04: Stern Investor Relations, Inc. (“Stern IR”) to provide strategic advisory services, enhance and execute the Company’s investor relations program and support ongoing efforts to expand visibility within the North American investment community in compliance with regulatory guidelines.")

MD
Bullboard Posts